Nektar Therapeutics (NASDAQ: NKTR) starts quiet period before Phase 2b REZOLVE-AD maintenance data

Rhea-AI Filing Summary

Nektar Therapeutics is entering a quiet period starting January 27, 2026 as it prepares analyses of 36-week maintenance data from its Phase 2b REZOLVE-AD study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. During this time, the company plans to limit public communications about these data.

The quiet period is described as consistent with Nektar’s prior practices for its REZOLVE studies and planned data disclosures. The next planned investor communication is expected in February 2026, when the company plans to present the maintenance data.

false 0000906709 0000906709 2026-01-27 2026-01-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 27, 2026

NEKTAR THERAPEUTICS

(Exact Name of Registrant as Specified in Charter)

Delaware		0-24006		94-3134940
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

455 Mission Bay Boulevard South

San Francisco, California 94158

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (415) 482-5300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		NKTR		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD.

As Nektar Therapeutics (the “Company”) prepares for analyses of data (the “Maintenance Data”) from the 36-week maintenance period of its Phase 2b REZOLVE-AD study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis, the Company is entering a quiet period beginning January 27, 2026 and continuing until the public announcement of the data. The implementation of the quiet period is consistent with the Company’s prior quiet periods pertaining to the Phase 2b REZOLVE studies and planned data disclosures. The Company’s next planned investor communication is expected in February 2026 at the time of the presentation of the Maintenance Data.

The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEKTAR THERAPEUTICS
Date: January 27, 2026	By:	/s/ Elizabeth Zhang
		Elizabeth Zhang
		Vice President, Legal

2

FAQ

What did Nektar Therapeutics (NKTR) disclose in this 8-K?

Nektar Therapeutics disclosed that it is entering a quiet period beginning January 27, 2026 while it prepares analyses of 36-week maintenance data from its Phase 2b REZOLVE-AD study of rezpegaldesleukin in moderate-to-severe atopic dermatitis.

Why is Nektar Therapeutics (NKTR) entering a quiet period?

The company is entering a quiet period to prepare analyses of the 36-week Maintenance Data from its Phase 2b REZOLVE-AD study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis.

How long will Nektar’s quiet period related to REZOLVE-AD last?

The quiet period begins on January 27, 2026 and continues until the public announcement of the 36-week maintenance data from the Phase 2b REZOLVE-AD study.

When is Nektar Therapeutics’ next planned investor communication?

The next planned investor communication is expected in February 2026, at the time of the presentation of the 36-week maintenance data from the Phase 2b REZOLVE-AD study.

Does this Nektar (NKTR) 8-K include financial results or guidance?

The 8-K focuses on the company’s quiet period and upcoming disclosure of Phase 2b REZOLVE-AD maintenance data, and describes the information in Item 7.01 as being furnished rather than filed.

What stage is Nektar’s REZOLVE-AD study in for rezpegaldesleukin?

The disclosure relates to the 36-week maintenance period of a Phase 2b REZOLVE-AD study evaluating rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis.